论文信息 - Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients - 字舞流文

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients

M. Karsdal | J. Trotter | G. Hirschfield | U. Beuers | S. Harrison | D. Leeming | L. Ling | H. Lieu | A. Paredes | A. DePaoli | A. Yan

[1] M. Karsdal,et al. Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis? , 2020, Hepatology.

[2] J. Trotter,et al. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis , 2019, Hepatology.

[3] M. Karsdal,et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. , 2019, Journal of hepatology.

[4] J. Trotter,et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2018, The Lancet.

[5] T. Arora,et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. , 2014, Cancer research.